Beyond Tissue: Liquid Biopsy Quantification of RAS Mutations and Proteomic Profiling for Patient Selection and Longitudinal Trial Monitoring

• Plasma cfDNA testing provides a real-time view of systemic tumor burden, helping reduce false negatives and identify patients with low-abundance or subclonal RAS variants for targeted therapy trials
• Rapid plasma cfDNA assays speed patient onboarding and trial recruitment, while longitudinal RAS monitoring enables earlier assessment of efficacy, response depth, and non-response
• Liquid biopsy proteomics can reveal non-genomic resistance mechanisms, immune microenvironment changes, and proteomic endotypes for deeper patient stratification
• Biodesix can help design and execute a customized RAS biomarker program that integrates genomic and proteomic insights 

Speakers:

Michael Sweeney

Director, Alliance Management, Business Development Operations

Biodesix